![PDF) Effect On Cardiac Function Among Patients With Type 2 Diabetes Following High-Dose Mineralocorticoid Receptor Antagonist Using Echocardiography; Data From The MIRAD Randomized Clinical Trial PDF) Effect On Cardiac Function Among Patients With Type 2 Diabetes Following High-Dose Mineralocorticoid Receptor Antagonist Using Echocardiography; Data From The MIRAD Randomized Clinical Trial](https://i1.rgstatic.net/publication/351825894_Effect_On_Cardiac_Function_Among_Patients_With_Type_2_Diabetes_Following_High-Dose_Mineralocorticoid_Receptor_Antagonist_Using_Echocardiography_Data_From_The_MIRAD_Randomized_Clinical_Trial/links/60ac4c78299bf1031fc854ee/largepreview.png)
PDF) Effect On Cardiac Function Among Patients With Type 2 Diabetes Following High-Dose Mineralocorticoid Receptor Antagonist Using Echocardiography; Data From The MIRAD Randomized Clinical Trial
Jon Brandt Jacobsen – Vice President / Partner - Digital Strategy & Transformation – Monstarlab | LinkedIn
![PDF) Effect on cardiac function among patients with type 2 diabetes following high-dose mineralocorticoid receptor antagonist using echocardiography; data from the MIRAD randomized clinical trial PDF) Effect on cardiac function among patients with type 2 diabetes following high-dose mineralocorticoid receptor antagonist using echocardiography; data from the MIRAD randomized clinical trial](https://i1.rgstatic.net/publication/369689123_Effect_on_cardiac_function_among_patients_with_type_2_diabetes_following_high-dose_mineralocorticoid_receptor_antagonist_using_echocardiography_data_from_the_MIRAD_randomized_clinical_trial/links/642796a4315dfb4ccec32b7c/largepreview.png)